How PhD was paid
$3.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Jean-Pierre Sommadossi, PhDPresident, Chief Executive Officer and Chairman of the Board | $703,490 | $1,315,800 | $962,368 | $422,094 | $0 | $3,403,752 |
| Andrea CorcoranChief Financial Officer, Executive Vice President, Legal | $549,530 | $442,170 | $437,440 | $247,288 | $14,000 | $1,690,428 |
| Janet Hammond, MD, PhDChief Development Officer | $590,892 | $459,000 | $437,440 | $265,902 | $14,000 | $1,767,234 |
| Maria Arantxa Horga, MDChief Medical Officer | $523,644 | $425,034 | $421,692 | $209,458 | $14,000 | $1,593,827 |
| John VavrickaChief Commercial Officer | $443,169 | $292,842 | $290,460 | $177,268 | $14,000 | $1,217,738 |
What changed and why
- $3.4MJean-Pierre Sommadossi received total compensation of $3,403,752 in 2025, decreasing from $4,202,323 in 2024.
- $1.3MStock awards for the CEO consisted solely of performance stock units valued at $1,315,800.
- $962KOption awards for the CEO totaled $962,368 based on grant date fair value.
- $422KNon-equity incentive plan compensation for the CEO was $422,094 for performance-based cash bonuses.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.